Axel Bolte
Investment Advisor, HBM Partners

Axel Bolte is an Investment Advisor at HBM Partners AG, a provider of investment advisory services in the life sciences industry. He joined HBM Partners AG from NMT New Medical Technologies, the first Swiss Venture Capital group focused exclusively on the life sciences. Previously, Mr. Bolte was with Serono SA, where he held a position in R&D management. He is a director of several public and private biotech companies, including Newron Pharmaceuticals SpA (SWX: NWRN; Milan, Italy), Nabriva Therapeutics GmbH (Vienna, Austria), PTC Therapeutics, Inc. (South Plainfield, NJ) and Lux Biosciences, Inc. (Jersey City, NJ). Mr. Bolte holds an MBA from the University of St. Gallen (HSG). He studied biochemistry and organic chemistry at the Swiss Federal Institute of Technology in Zurich (ETH) and at the University of Cambridge, UK, where he focused on the synthesis of complex natural products of marine origin.